- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07698314
A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer (Myo-EXERTBC)
Myo-EXERTBC: A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer
In this pilot study, the investigators will assess the changes in myokine production based on several different exercise regimens.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Clinical Trials Contact
- Phone Number: 412-330-6151
- Email: ctgov@ahn.org
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Recruiting
- Allegheny General Hospital
-
Contact:
- Clinical Trials Contact
- Phone Number: 4123306151
- Email: ctgov@ahn.org
-
Pittsburgh, Pennsylvania, United States, 15212
- Not yet recruiting
- AHN Allegheny General Hospital
-
Contact:
- Clinical Trials Contact
- Phone Number: 412-330-6151
- Email: clinicaltrials@ahn.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 20-89 years
- Women prescribed exercise as a SOC
- Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
- Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
- Women with > 3 months of resistance training experience under expert guidance at the Allegheny Health Network Exercise Oncology Center
Exclusion Criteria:
- Any current treatment with cytotoxic chemotherapy for breast cancer
- Inability to safely engage in group sessions of resistance training as deemed by study PI
- Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
- Pregnant women
- Males
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Conditioning Regimen Group
|
Participants in this group will perform a conditioning regimen from the EXERT-BCHC protocol, specifically described as "double training". |
|
Experimental: Strength Regimen Group
|
Participants in this group will perform a strength regimen from the EXERT-BCHC protocol, specifically described as "8x8". |
|
Experimental: Hypertrophy Regimen Group
|
Participants in this group will perform a hypertrophy regimen from the EXERT-BCHC protocol, specifically described as the "control arm". |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Myokine Production After First Exercise Session
Time Frame: Immediately before and immediately after the first exercise session.
|
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples. The change from pre-exercise to post-exercise levels will be determined. |
Immediately before and immediately after the first exercise session.
|
|
Change in Myokine Production After Final Exercise Session of Each Week
Time Frame: Immediately before and immediately after the final exercise session of weeks 1, 2, 3, and 4.
|
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the end of each week will be determined. |
Immediately before and immediately after the final exercise session of weeks 1, 2, 3, and 4.
|
|
Change in Myokine Production After Final Exercise Session of the Month (End of Study)
Time Frame: Immediately before and immediately after the final exercise session of week 4 (end of the 4-week exercise regimen).
|
Quantification of a panel of 15 myokines (IL-5, IL-1ra, LIF, Irisin, SPARC, Decorin, Oncostatin M, Myostatin, Follistatin, Apelin, Fibroblast Growth Factor 21 (FGF21), Cathepsin-B, IL-15, METRNL, Myonectin) in both serum and tear samples for each group. The change from pre-exercise to post-exercise levels at the culmination of the 4-week exercise period will be determined. |
Immediately before and immediately after the final exercise session of week 4 (end of the 4-week exercise regimen).
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Colin Champ, MD, AHN Radiation Oncology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Skin Diseases
- Breast Diseases
- Skin and Connective Tissue Diseases
- Neoplasms
- Breast Neoplasms
- Motor Activity
- Movement
- Musculoskeletal Physiological Phenomena
- Musculoskeletal and Neural Physiological Phenomena
- Therapeutics
- Physical Therapy Modalities
- Patient Care
- Exercise Therapy
- Rehabilitation
- Aftercare
- Continuity of Patient Care
- Physical Conditioning, Human
- Exercise
- Resistance Training
Other Study ID Numbers
- 2026-125
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.